Galmed Pharmaceuticals to Present Late-Breaking Abstract
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has announced an exciting development in its research on Aramchol. A late-breaking abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib" will be presented as a poster during a prestigious scientific meeting. This moment is especially anticipated as it highlights significant advancements in the treatment strategies for hepatocellular carcinoma.
Significance of the Research
The research has shown that Aramchol has a profound impact on enhancing the effectiveness of Bayer's drug regorafenib in treating gastrointestinal cancer. Findings indicate SCD1 inhibition can amplify the effects of regorafenib, leading to improved outcomes against tumor cells. This discovery provides a solid foundation for initiating a Phase 1/2 clinical trial that will explore the combination of Aramchol and regorafenib for treating hepatocellular carcinoma and other gastrointestinal cancers.
Future Plans for Clinical Trials
Following this research, Galmed plans to proceed with a Phase 1/2 clinical trial to further investigate this innovative treatment combination. This trial will evaluate its efficacy while exploring the addition of Metformin, broadening the potential therapeutic impact. The anticipation surrounding the results of this trial is high, with enrollment set to initiate in the near future, paving the way for accelerated clinical development of Aramchol.
Insights from Leadership
Allen Baharaff, the CEO of Galmed Pharmaceuticals, expressed enthusiasm over the acceptance of the late-breaking abstract, noting that it emphasizes the relevance of the findings shared at such respected gatherings. He comments that these insights have helped guide clinical decisions at VCU Massey Comprehensive Cancer Center, further validating Galmed's commitment to advancing cancer treatment.
The Role of HEP-DART Conference
The HEP-DART conference plays a critical role in uniting experts in the fields of drug development and liver diseases. Since its inception, it serves as a vital platform for discussing major advancements in the treatment of liver infections, including hepatocellular carcinoma. The upcoming 2025 meeting aims to gather clinicians and researchers to further the collective understanding of drug development challenges in tackling liver diseases.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is dedicated to the innovative development of its flagship drug, Aramchol, primarily targeting liver-related health conditions. This strategic focus extends to addressing complex oncological indications as well. By striving to enhance and diversify its product pipeline, Galmed actively seeks to bring new solutions to the forefront of patient care, particularly in the cardiometabolic arena.
Commitment to Continuous Development
The company continues to pursue ambitious growth strategies while being dedicated to bringing innovative therapies to patients who need them the most. This commitment reflects Galmed's ambition not just to address current medical needs but also expand into future therapeutic avenues to enhance patient outcomes.
Frequently Asked Questions
What is the focus of Galmed Pharmaceuticals?
Galmed is centered on developing Aramchol, primarily for liver diseases and some oncological indications.
What was presented at the HEP-DART conference?
A late-breaking abstract discussing the combination of Aramchol and regorafenib for treating liver cancer and gastrointestinal cancers was presented.
What findings were highlighted about Aramchol?
Aramchol demonstrates enhanced activity with regorafenib, improving treatment efficacy against gastrointestinal cancer cells.
When is the Phase 1/2 clinical trial expected to begin?
Enrollment for the Phase 1/2 clinical trial is expected to start shortly, paving the way for further research.
How does Galmed contribute to cancer treatment development?
Galmed focuses on delivering innovative therapeutic strategies, partnering with research institutions to explore advanced treatment combinations.
